Research programme: androgen-based therapeutics - CPEX

Drug Profile

Research programme: androgen-based therapeutics - CPEX

Latest Information Update: 14 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bentley Pharmaceuticals; Dartmouth College; Dartmouth Medical School
  • Developer CPEX Pharmaceuticals; Dartmouth College; Dartmouth Medical School
  • Class Testosterone congeners
  • Mechanism of Action Testosterone congener stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic fatigue syndrome; Fibromyalgia; Male osteoporosis

Most Recent Events

  • 06 Aug 2009 No development reported - Clinical-Phase-Unknown for Fibromyalgia in USA (Topical)
  • 23 Jul 2008 Bentley Pharmaceuticals has been acquired by Teva Pharmaceutical Industries
  • 25 Mar 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top